Conferences:
Aicha Boudhar, Kevin S. W. Tan. Reversing Chloroquine-Resistancein Malaria Parasites: New compounds and Tools against a Persistent Foe. Gordon Research Seminar Medicinal Chemistry, New London (NH), USA, 04/05 August 2013.
See Cheng Shang, Brian W Dymock. Exploring Surface Plasmon Resonance (SPR) Technology for the Discovery and Evaluation of MKlp2 Inhibitors. 4th A*STAR Chemistry Symposium, Singapore, 19th February 2014.
Feng Wei, Brian W Dymock. Synthesis of new H2S releasing compounds, H2S concentration determinations, SAR studies and anticancer bioactivity. 4th A*STAR Chemistry Symposium, Singapore, 19th February 2014.
Uttara, Brian W Dymock, Development of G9a Inhibitors for the treatment of Muscular Dystrophy and Cancer, 4th A*STAR Chemistry Symposium, Singapore, 19th February 2014. Award: Best Poster Prize.
Peh Kai Yi Kaye, Brian W Dymock. Development of novel slow H2S releasing compounds as potential anti-cancer agents. Final Year Project Poster Presentation, National University of Singapore, Singapore, 15th April 2014. Award: 3rd Prize by Royal Chemical Society (RSC).
Aicha Boudhar, Brian W Dymock, Kevin S. W. Tan. Reversing Chloroquine-Resistance in Malaria Parasites: New compounds and Tools against a Persistent Foe. Drug Design & Medicinal Chemistry Conference, Berlin (Germany), 08/09 May 2014.
Invited Oral Presentations (A/Prof Dymock, Brian William):
Discovery of the JAK2/FLT3 Inhibitor Pacritinib and the Creation of Designed Bispecific Molecules Inhibiting Both JAK2 and HDAC at Low Nanomolar Concentrations’, Drug discovery and development – Global Scenario – Indian Perspective, NIPER, Hyderabad, India, 21-22 Nov 2015 (session chair, speaker and panel speaker).
‘Preclinical Development and Beyond’, A*STAR Drug Discovery and Development Course, Sep 2015.
‘What is Medicinal Chemistry Anyway? The Basics of Chemical Bench-to-Bedside Illustrated with Case Studies of New Drugs Discovered in Singapore’, Duke-NUS, 12th June 2015.
‘Safe Handling and Storage of Pyrophoric Chemicals’, 2nd NUS Safety, Health and Environment Conference, 14th May 2015.
‘Could two be better than one? De-Focusing Targeted Agents Through Creation of Bispecific Molecules Inhibiting Two Validated Target Types For The Treatment of Resistant Disease’, 1st GIN-RSC Symposium, Singapore, 13th April 2015 (keynote speaker)
‘Advances in the Identification of Lead Molecules (with a focus on Fragment Screening)’, Merck, Sharpe and Dohme Drug Discovery Workshop, 4th March 2015 (and panel member).
Pyrophorics Workshop, Science Safety Day, NUS 22nd Sept 2014 (live and videographed for training)
‘Preclinical Development and Beyond, A*STAR Drug Discovery and Development Course, Sep 2014.
‘Potential Applications of Molecular Sensors in the Pharmaceutical Industry’, Singapore Sensor Centre Workshop, Singapore, 26th July 2014.
‘Drug Discovery and Development: careers in biomedical science’, BioBiz 2014, NUS, Singapore, 5th April 2014.
‘Journeys in kinase inhibitor research leading to Pacritininb and other clinical candidates’, presentation to GSK Singapore Research Centre, 26 Nov 2013.
'Journeys in kinase inhibitor research leading to Pacritininb and other clinical candidates’, 1st International Symposium of Drug Designology, Hainan, China, 15 Nov 2013. (Session Chair and Presenter)
‘Pacritininb (SB1518), a JAK2/FLT3 inhibitor for the treatment of Myelofibrosis and Lymphoma: Discovery, Development and Clinical Responses’, ITB International Pharmacy Symposium, Dept of Pharmacy, NUS, 12 Nov 2013.
‘Preclinical Development and Beyond, A*STAR Drug Discovery and Development Course, 30 Sep 2013.
‘Drug Discovery and Development: careers in biomedical science’, Republic Polytechnic, Singapore, 20th May 2013.
‘Molecular Lego: Capturing the Imagination’, Internal Seminar, Dept of Pharmacy, NUS, 17th May 2013.
‘Introduction to the Drug Development Process’, Singapore Guideline for Good Clinical Practice Course, National Healthcare Group Research & Development Office (NHG RDO), 13th May 2013
‘Designing the Heart of a New Medicine: the NUS Drug Development Unit (DDU)’, Dept of Biochemisty, NUS, 25 Feb 2013.
NMRC AWARD CEREMONY AND TCR SYMPOSIUM 2012, Intellectual Property & Commercialisation workshop, Resorts World Sentosa Convention Centre, 1st Nov 2012
Invited Talk on ‘The NUS Drug Development Unit’, Duke-NUS, Singapore, 11th Oct 2012.
B.W. Dymock “Searching for the needle in the haystack: finding novel biologically active molecules as potential therapeutics against new biological mechanisms”, NUS Annual Pharmacy Research Symposium, Singapore, 4th April 2012
Discovery of Low Molecular Weight Kinase Inhibitors for Important Pathways in Cancer and Autoimmune Disease: Discovery of the JAK2 Inhibitor Pacritinib (SB1518), Dymock, B. W. 9th BIT Annual Congress of International Drug Discovery Science and Technology, Shenzen, China; 4th Nov 2011(Session Chair and Presenter).
B.W. Dymock “Creation of new medicines: how the medicinal chemist can transform lives with good science, teamwork and small resources”, Nanyang Technological University, Singapore, 18th July 2011
B.W. Dymock “Falling off the permeability cliff: balancing molecular properties in the design of potent orally available PDK1 inhibitors for the treatment of cancer “, NUS Pharmacy Medicinal Chemistry Symposium, Singapore, 1-2 September 2010.
B.W. Dymock “How to make real drugs the Singapore way: fast, furious and fun”, UK-Singapore Medicinal Chemistry Symposium, Biopolis, Singapore, 28th January 2010.
B.W. Dymock “SB939: the story of Singapore’s first home-grown small molecule oncology drug”, UK-Singapore Medicinal Chemistry Symposium, Biopolis, Singapore, 16th October 2008.